These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 29239101)

  • 1. Acquired Von Willebrand syndrome and response to desmopressin.
    Biguzzi E; Siboni SM; Peyvandi F
    Haemophilia; 2018 Jan; 24(1):e25-e28. PubMed ID: 29239101
    [No Abstract]   [Full Text] [Related]  

  • 2. The utility of the DDAVP challenge test in children with low von Willebrand factor.
    Archer NM; Samnaliev M; Grace R; Brugnara C
    Br J Haematol; 2015 Sep; 170(6):884-6. PubMed ID: 25733073
    [No Abstract]   [Full Text] [Related]  

  • 3. Prophylaxis in von Willebrand disease.
    Franchini M; Targher G; Lippi G
    Ann Hematol; 2007 Oct; 86(10):699-704. PubMed ID: 17634944
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A retrospective study of the utility of desmopressin (1-deamino-8-D-arginine vasopressin) trials in the management of patients with von Willebrand disorder.
    Shortt J; Opat SS; Gorniak MB; Aumann HA; Collecutt MF; Street AM
    Int J Lab Hematol; 2010 Feb; 32(1 Pt 1):e181-3. PubMed ID: 19016919
    [No Abstract]   [Full Text] [Related]  

  • 5. No influence of blood group on the responsiveness to desmopressin in type I "platelet normal" von Willebrand's disease.
    Castaman G; Rodeghiero F
    Thromb Haemost; 1995 Mar; 73(3):551-2. PubMed ID: 7667843
    [No Abstract]   [Full Text] [Related]  

  • 6. Assessment of primary haemostasis with a new recombinant von Willebrand factor in patients with von Willebrand disease.
    Trossaërt M; Flaujac C; Jeanpierre E; Drillaud N; Sigaud M; Fouassier M; Ternisien C; de Raucourt E
    Haemophilia; 2020 Mar; 26(2):e44-e48. PubMed ID: 31865618
    [No Abstract]   [Full Text] [Related]  

  • 7. Efficacy of adjusted weight-based dosing of desmopressin (1-deamino-8-d-arginine vasopressin in type 1 von Willebrand disease.
    Seaman CD
    Blood Coagul Fibrinolysis; 2023 Oct; 34(7):462-464. PubMed ID: 37823430
    [No Abstract]   [Full Text] [Related]  

  • 8. Platelet ristocetin cofactor (RiCof) in patients with type I "platelet normal" von Willebrand disease correlates with plasma RiCof peak after desmopressin infusion.
    Castaman G; Rodeghiero F
    Thromb Res; 1995 Feb; 77(4):383-4. PubMed ID: 7740531
    [No Abstract]   [Full Text] [Related]  

  • 9. Desmopressin: a nontransfusional treatment of hemophilia and von Willebrand disease.
    Mannucci PM; Cattaneo M
    Haemostasis; 1992; 22(5):276-80. PubMed ID: 1478539
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnosis and treatment of acquired von Willebrand syndrome.
    Tiede A
    Thromb Res; 2012 Dec; 130 Suppl 2():S2-6. PubMed ID: 23439003
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Von Willebrand disease: Clinical conundrums.
    Leebeek FWG; Susen S
    Haemophilia; 2018 May; 24 Suppl 6():37-43. PubMed ID: 29878657
    [No Abstract]   [Full Text] [Related]  

  • 12. Regulated release of VWF and FVIII and the biologic implications.
    Haberichter SL; Shi Q; Montgomery RR
    Pediatr Blood Cancer; 2006 May; 46(5):547-53. PubMed ID: 16470522
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of D-arginine vasopressin in von Willebrand's disease.
    Bala L; Boggio L; Green D
    Curr Hematol Rep; 2005 Jan; 4(1):1-2. PubMed ID: 15610653
    [No Abstract]   [Full Text] [Related]  

  • 14. Von Willebrand disease.
    Wilde JT
    Clin Med (Lond); 2007 Dec; 7(6):629-32. PubMed ID: 18193717
    [No Abstract]   [Full Text] [Related]  

  • 15. Acquired von Willebrand disease in twins with autoimmune hypothyroidism: response to desmopressin and L-thyroxine therapy.
    Bruggers CS; McElligott K; Rallison ML
    J Pediatr; 1994 Dec; 125(6 Pt 1):911-3. PubMed ID: 7996364
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Response to DDAVP in von Willebrand disease type II C].
    Batllé Fonrodona J; López Fernández MF; Martín González R; Fernández Villamor A; López Borrasca A; Lasierra Cirujeda J
    Sangre (Barc); 1985; 30(2):181-4. PubMed ID: 3925573
    [No Abstract]   [Full Text] [Related]  

  • 17. Update on the management of von Willebrand disease.
    Federici AB
    Clin Adv Hematol Oncol; 2008 Jan; 6(1):29-30. PubMed ID: 18322438
    [No Abstract]   [Full Text] [Related]  

  • 18. Von Willebrand factor (Vonvendi®): the first recombinant product licensed for the treatment of von Willebrand disease.
    Franchini M; Mannucci PM
    Expert Rev Hematol; 2016 Sep; 9(9):825-30. PubMed ID: 27427955
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mild forms of von Willebrand disease: diagnosis and management.
    Federici AB
    Curr Hematol Rep; 2003 Sep; 2(5):373-80. PubMed ID: 12932308
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recombinant von Willebrand factor.
    Schwarz HP; Turecek PL; Pichler L; Mitterer A; Mundt W; Dorner F; Roussi J; Drouet L
    Thromb Haemost; 1997 Jul; 78(1):571-6. PubMed ID: 9198218
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.